主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
COYA
#3330
Coya Therapeutics, Inc. Common Stock
4.9
6
+1.22%
版块:
基础:
利润货币:
日范围
年范围
日变化
+1.22%
每月变动
+2.06%
6个月变化
-25.30%
年变化
-24.04%
前一天收盘价
4.9
0
Open
4.9
6
Bid
Ask
Low
4.9
6
High
4.9
6
交易量
2
市场
股票
医疗保健
COYA
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Key stats
Total common shares outstanding
9.95 M
14.54 M
16.72 M
—
Valuation ratios
Enterprise value
49.12 M
77.41 M
57.53 M
287.78 M
Price to earnings ratio
-0.98
-8.81
-5.85
-21.67
Price to sales ratio
—
11.79
24.57
301.44
Price to cash flow ratio
-1.66
-6.32
-8.49
-28.15
Price to book ratio
-0.7
2.64
2.21
4.31
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-1.46
-0.19
-0.34
-0.5
Return on equity %
1.46
-0.22
-0.38
-0.59
Return on invested capital %
-3 242.01
-1 210.43
-1 730.96
—
Gross margin %
—
100
100
400
Operating margin %
—
-131.67
-485.35
-216 K
EBITDA margin %
—
—
—
—
Net margin %
—
-133.08
-418.7
-155.99 K
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
1.88
8.15
11.59
36.58
Inventory turnover
—
—
—
—
Asset turnover
—
0.24
0.08
0.12
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
1.54
—
—
—
Long term debt to total equity ratio
-1.54
—
—
—
Per share metrics
Operating cash flow per share
-2.79
-1.1
-0.68
-0.74
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
2.29
3.21
2.51
8.1
Net current asset value per share
2.77
4.05
2.91
9.12
Tangible book value per share
-6.64
2.64
2.6
7.92
Working capital per share
1.3
3.56
2.66
8.12
Book value per share
-6.64
2.64
2.6
7.92
新闻
H.C. Wainwright 维持Coya Therapeutics股票买入评级,目标价18美元
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock with $18 target
Coya Therapeutics完成1110万美元私募融资
Coya Therapeutics secures $11.1 million in private placement
Coya Therapeutics推进ALS和FTD临床试验至2026年
Coya Therapeutics advances ALS and FTD clinical trials in 2026
H.C. Wainwright维持Coya Therapeutics股票18美元的买入评级
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18
Tracking David Einhorn’s Greenlight Capital Portfolio – Q3 2025 Update (NYSE:GRBK)
H.C. Wainwright重申Coya Therapeutics股票买入评级
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock
H.C. Wainwright重申Coya Therapeutics股票买入评级,目标价18美元